Skip to content
Screener

Stoke Therapeutics, Inc. STOK Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$13.8MBeat by $8.5M
EPS-$0.40Beat by $0.17
Revenue estimate$5.4M
EPS estimate-$0.57

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.2M
EPS estimate-$0.88

Financials

Q2 2025

Income statement

See full
Revenue$13.8M+186%
Operating income-$27.3M+7.0%
Net income-$23.5M+8.6%
EPS (diluted)-$0.40+13.0%

Balance sheet

See full
Cash & equivalents$101.5M-47.6%
Total debt$5.3M-9.3%
Total equity$334.9M+38.0%
Total assets$384.5M+24.9%

Cash flow

See full
CapEx$154.0K+235%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$628.41M+0.6%
Enterprise value$532.22M+21.7%
P/E12×—
P/S3.1×-38.1×

Profitability

See full
Operating margin20.2%+10.2pp
Net margin26.3%+13.4pp

Returns & leverage

See full
Return on equity18.2%+10.5pp
Debt / equity0×0.0×
Current ratio7×+0.3×

FAQ

When did Stoke Therapeutics, Inc. report Q2 2025 earnings?
Stoke Therapeutics, Inc. (STOK) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Stoke Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Stoke Therapeutics, Inc. reported revenue of $13.8M and eps of $-0.40 for Q2 2025.
Did Stoke Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $5.4M by $8.5M. EPS beat the consensus estimate of $-0.57 by $0.17.
How did Stoke Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 186.0% from $4.8M a year earlier and eps grew 13.0% from $-0.46.
Where can I find Stoke Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-177433) and the 10-Q periodic report (0000950170-25-107332) directly on SEC EDGAR. The filing index links above go to sec.gov.